CN107249591B - 固体药物配制品及其制备方法 - Google Patents

固体药物配制品及其制备方法 Download PDF

Info

Publication number
CN107249591B
CN107249591B CN201580063476.2A CN201580063476A CN107249591B CN 107249591 B CN107249591 B CN 107249591B CN 201580063476 A CN201580063476 A CN 201580063476A CN 107249591 B CN107249591 B CN 107249591B
Authority
CN
China
Prior art keywords
amount
compound
epz
pharmaceutical formulation
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580063476.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN107249591A (zh
Inventor
海克·凯尔哈克
布雷特·特鲁伊特
铃木雄太
村濑池沙
鹿田太志
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanitary Material R&d Management Co ltd
Epizyme Inc
Original Assignee
Sanitary Material R&d Management Co ltd
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanitary Material R&d Management Co ltd, Epizyme Inc filed Critical Sanitary Material R&d Management Co ltd
Priority to CN202310518396.8A priority Critical patent/CN116650500A/zh
Publication of CN107249591A publication Critical patent/CN107249591A/zh
Application granted granted Critical
Publication of CN107249591B publication Critical patent/CN107249591B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
CN201580063476.2A 2014-11-17 2015-11-17 固体药物配制品及其制备方法 Active CN107249591B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310518396.8A CN116650500A (zh) 2014-11-17 2015-11-17 治疗癌症的方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462080985P 2014-11-17 2014-11-17
US62/080,985 2014-11-17
US201562166572P 2015-05-26 2015-05-26
US62/166,572 2015-05-26
US201562251903P 2015-11-06 2015-11-06
US62/251,903 2015-11-06
PCT/US2015/061194 WO2016081523A1 (en) 2014-11-17 2015-11-17 Method for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310518396.8A Division CN116650500A (zh) 2014-11-17 2015-11-17 治疗癌症的方法

Publications (2)

Publication Number Publication Date
CN107249591A CN107249591A (zh) 2017-10-13
CN107249591B true CN107249591B (zh) 2024-01-30

Family

ID=56014476

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580063476.2A Active CN107249591B (zh) 2014-11-17 2015-11-17 固体药物配制品及其制备方法
CN202310518396.8A Pending CN116650500A (zh) 2014-11-17 2015-11-17 治疗癌症的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310518396.8A Pending CN116650500A (zh) 2014-11-17 2015-11-17 治疗癌症的方法

Country Status (21)

Country Link
US (3) US10786511B2 (OSRAM)
EP (2) EP3220916B1 (OSRAM)
JP (3) JP6829684B2 (OSRAM)
KR (3) KR20240035908A (OSRAM)
CN (2) CN107249591B (OSRAM)
AU (3) AU2015350108B2 (OSRAM)
BR (1) BR112017010166A2 (OSRAM)
CA (1) CA2967664A1 (OSRAM)
DK (1) DK3220916T3 (OSRAM)
EA (1) EA201791095A1 (OSRAM)
ES (1) ES2947819T3 (OSRAM)
FI (1) FI3220916T3 (OSRAM)
HU (1) HUE062159T2 (OSRAM)
IL (4) IL296080B2 (OSRAM)
LT (1) LT3220916T (OSRAM)
MX (2) MX383484B (OSRAM)
PL (1) PL3220916T3 (OSRAM)
PT (1) PT3220916T (OSRAM)
SG (1) SG11201703806XA (OSRAM)
SI (1) SI3220916T1 (OSRAM)
WO (1) WO2016081523A1 (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
AU2013331368A1 (en) 2012-10-15 2015-04-30 Epizyme, Inc. Methods of treating cancer
ES2863996T3 (es) 2013-12-06 2021-10-13 Epizyme Inc Terapia de combinación para el tratamiento del cáncer
JP6779793B2 (ja) 2014-06-17 2020-11-04 エピザイム，インコーポレイティド リンパ腫を治療するためのｅｚｈ２阻害剤
HUE062159T2 (hu) 2014-11-17 2023-10-28 Epizyme Inc Módszer a rák kezelésére N-((4,6-dimetil-2-oxo-l,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H -pirán-4-il)amino)-4-metil-4'-(morfolinmetil)-[1,1'-bifenil]-3-karboxamiddal
MX391720B (es) 2015-04-20 2025-03-21 Epizyme Inc Terapia combinada para tratar cáncer.
MX387885B (es) 2015-06-10 2025-03-19 Epizyme Inc Inhibidores de ezh2 para tratar linfomas.
WO2017035234A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
EP3407978A4 (en) 2016-01-29 2020-01-15 Epizyme Inc POLYTHERAPY FOR THE TREATMENT OF CANCER
EP3464643A4 (en) 2016-06-01 2020-04-01 Epizyme Inc USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER
MA45406A (fr) 2016-06-17 2019-04-24 Epizyme Inc Inhibiteurs d'ezh2 pour traiter le cancer
AU2018210099A1 (en) 2017-01-19 2019-08-15 Daiichi Sankyo Company, Limited Pharmaceutical composition used for treatment of HTLV-1-associated myelopathy
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
AU2018275123A1 (en) 2017-06-02 2020-01-30 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
CA3074720A1 (en) 2017-09-05 2019-03-14 Epizyme, Inc. Combination therapy for treating cancer
IL294108A (en) * 2019-12-20 2022-08-01 Epizyme Inc Crystalline hydrobromide salt of a ezh2 inhibitor, its preparation and pharmaceutical composition useful for the treatment of cancer
JP7628876B2 (ja) 2021-04-23 2025-02-12 日立Astemo株式会社 情報処理装置、情報処理方法、プログラムおよび記憶媒体
WO2023159124A2 (en) * 2022-02-17 2023-08-24 Memorial Sloan-Kettering Cancer Center Methods for overcoming tazemetostat-resistance in cancer patients
EP4514391A1 (en) 2022-04-27 2025-03-05 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100080A1 (en) * 2012-12-19 2014-06-26 Glaxosmithkline Llc Combination
CN106999498A (zh) * 2014-06-17 2017-08-01 Epizyme股份有限公司 用于治疗淋巴瘤的ezh2抑制剂

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119052D0 (en) 1991-09-06 1991-10-23 Boots Co Plc Pharmaceutical compositions
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20070026064A1 (en) * 2005-07-29 2007-02-01 Yoder Steven L Pharmaceutical dosage forms having watermark-type identification and authentication inditia
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
RU2765155C2 (ru) * 2010-09-10 2022-01-26 Эпизайм, Инк. Ингибиторы ezh2 человека и способы их применения
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
WO2012097222A1 (en) * 2011-01-14 2012-07-19 Bristol-Myers Squibb Company High drug load tablet formulation of brivanib alaninate
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
EP3536314A1 (en) * 2012-03-12 2019-09-11 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
EP2836216B1 (en) * 2012-04-13 2022-06-08 Epizyme, Inc. Combination therapy for treating cancer
SG10201608577RA (en) * 2012-04-13 2016-12-29 Epizyme Inc Salt form of a human hi stone methyltransf erase ezh2 inhibitor
NZ706738A (en) 2012-10-15 2018-10-26 Epizyme Inc Substituted benzene compounds
AU2013331368A1 (en) * 2012-10-15 2015-04-30 Epizyme, Inc. Methods of treating cancer
CA2894222A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
WO2014100646A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone compounds
WO2014172044A1 (en) 2013-03-15 2014-10-23 Epizyme, Inc. Substituted benzene compounds
EP2970306A4 (en) 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS
EP3022184B1 (en) 2013-07-19 2017-09-27 Epizyme, Inc. Substituted benzene compounds
LT3057962T (lt) * 2013-10-16 2023-12-11 Epizyme, Inc. Hidrochlorido druskos forma, skirta ezh2 inhibavimui
WO2015058125A1 (en) 2013-10-18 2015-04-23 Epizyme, Inc. Method of treating cancer
ES2863996T3 (es) 2013-12-06 2021-10-13 Epizyme Inc Terapia de combinación para el tratamiento del cáncer
US20170217941A1 (en) 2014-06-25 2017-08-03 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
KR102397720B1 (ko) 2014-10-16 2022-05-13 에피자임, 인코포레이티드 암을 치료하기 위한 방법
HUE062159T2 (hu) * 2014-11-17 2023-10-28 Epizyme Inc Módszer a rák kezelésére N-((4,6-dimetil-2-oxo-l,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H -pirán-4-il)amino)-4-metil-4'-(morfolinmetil)-[1,1'-bifenil]-3-karboxamiddal
MX387885B (es) * 2015-06-10 2025-03-19 Epizyme Inc Inhibidores de ezh2 para tratar linfomas.
MA45406A (fr) * 2016-06-17 2019-04-24 Epizyme Inc Inhibiteurs d'ezh2 pour traiter le cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100080A1 (en) * 2012-12-19 2014-06-26 Glaxosmithkline Llc Combination
CN106999498A (zh) * 2014-06-17 2017-08-01 Epizyme股份有限公司 用于治疗淋巴瘤的ezh2抑制剂

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EZH2 Inhibitor EPZ-6438 (E7438) in Non-Hodgkin Lymphoma: Pre-Clinical Models and Early Clinical Observations;Robert A. Copeland等;《ASH Lymphoma Biology Meeting》;20140812;全文 *
Robert A. Copeland等.EZH2 Inhibitor EPZ-6438 (E7438) in Non-Hodgkin Lymphoma: Pre-Clinical Models and Early Clinical Observations.《ASH Lymphoma Biology Meeting》.2014, *
韦超等主编.片剂.《药剂学》.河南科学技术出版社,2012,第187页. *
高建青主编.常见药用辅料.《药剂学与工业药剂学实验指导》.浙江大学出版社,2012,第100-101页. *

Also Published As

Publication number Publication date
EP3220916A4 (en) 2018-07-11
JP2023062189A (ja) 2023-05-02
AU2015350108A1 (en) 2017-05-25
KR20170103768A (ko) 2017-09-13
PT3220916T (pt) 2023-06-26
BR112017010166A2 (en) 2018-02-14
LT3220916T (lt) 2023-07-25
IL296080A (en) 2022-11-01
HUE062159T2 (hu) 2023-10-28
IL296080B2 (en) 2023-12-01
JP2017537899A (ja) 2017-12-21
WO2016081523A1 (en) 2016-05-26
MX2017006089A (es) 2017-12-11
US20250064822A1 (en) 2025-02-27
MX383484B (es) 2025-03-11
NZ731696A (en) 2024-03-22
AU2015350108B2 (en) 2021-04-08
US20210060030A1 (en) 2021-03-04
KR20240035908A (ko) 2024-03-18
US12168014B2 (en) 2024-12-17
SG11201703806XA (en) 2017-06-29
IL252182A0 (en) 2017-07-31
IL252182B2 (en) 2023-02-01
CA2967664A1 (en) 2016-05-26
US20170360797A1 (en) 2017-12-21
KR20210156840A (ko) 2021-12-27
EP3220916B1 (en) 2023-04-19
NZ768247A (en) 2024-05-31
AU2024201171A1 (en) 2024-03-14
IL296080B1 (en) 2023-08-01
CN116650500A (zh) 2023-08-29
AU2021204706B2 (en) 2023-11-23
AU2021204706A1 (en) 2021-07-29
IL252182B (en) 2022-10-01
JP6829684B2 (ja) 2021-02-10
EA201791095A1 (ru) 2017-10-31
PL3220916T3 (pl) 2023-08-14
JP7485810B2 (ja) 2024-05-16
SI3220916T1 (sl) 2023-09-29
CN107249591A (zh) 2017-10-13
KR102338802B1 (ko) 2021-12-14
IL323396A (en) 2025-11-01
JP2021073241A (ja) 2021-05-13
IL304252B1 (en) 2025-11-01
IL304252A (en) 2023-09-01
MX2021006734A (es) 2021-07-02
KR102644844B1 (ko) 2024-03-07
DK3220916T3 (da) 2023-06-26
ES2947819T3 (es) 2023-08-21
EP3220916A1 (en) 2017-09-27
EP4272742A1 (en) 2023-11-08
FI3220916T3 (fi) 2023-06-19
US10786511B2 (en) 2020-09-29

Similar Documents

Publication Publication Date Title
CN107249591B (zh) 固体药物配制品及其制备方法
US11642349B2 (en) Method for treating cancer
JP2018529698A (ja) Ｅｚｈ２阻害剤により卵巣の悪性ラブドイド腫瘍（ｍｒｔｏ）／高カルシウム血症型の卵巣の小細胞癌（ｓｃｃｏｈｔ）を処置するための方法
TWI815820B (zh) ２－（５－（４－（２－嗎啉乙氧基）苯基）吡啶－２－基）－ｎ－芐乙醯胺之固態形式
HK40103478A (en) Epz-6438 for use in a method for treating cancer
EA048689B1 (ru) Твердый фармацевтический состав для лечения рака
JP2022522873A (ja) レボケトコナゾールによる疾患の処置方法
HK40074912B (zh) 用ezh2抑制剂治疗mrto/sccoht的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant